Business Context and Reporting Period
Company: Dyadic International, Inc. (DYAI)
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2021
Event: Entry into a Material Definitive Agreement (Binding Term Sheet) with Sorrento Therapeutics, Inc.
Key Financial Metrics and Transaction Terms
This filing details a strategic licensing agreement rather than standard periodic financial results. Key financial terms include:
- Up-Front License Fee: $10,000,000 total.
- $5,000,000 in cash.
- $5,000,000 in Sorrento Therapeutics restricted common stock.
- Development Cost Reimbursements: Up to $4,000,000 for preclinical and clinical costs incurred prior to the agreement's effective date.
- Milestone Payments: Up to $33,000,000 in non-refundable, non-creditable one-time payments upon achievement of specific events.
- Ongoing Royalties: To be received on sales of Licensed Products (specific rates not disclosed in this summary).
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for Dyadic International, Inc.
Material Changes and Transaction Scope
The primary material change is the execution of a Term Sheet to license Dyadic's C1 technology to Sorrento Therapeutics. Key scope details include:
- Assets Licensed: Patents, patent applications, know-how, trade secrets, and proprietary technology.
- Target Product: DYAI-100 (lead COVID-19 vaccine candidate) and other vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses.
- Geographic Rights: Exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan), and certain other countries.
- Field of Use: Exclusive license in the Human Field of Use; non-exclusive license in the Animal Field of Use.
- Timeline: Final License Agreement to be executed within 45 business days; up-front payment due within 30 days of execution.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement positions Dyadic to monetize its C1 technology platform through a partnership with Sorrento for the development and commercialization of coronavirus-related products.
Risks and Contingencies:
- Regulatory Approval: The stock portion of the up-front payment is contingent on Sorrento filing a Form S-3 registration statement and having it declared effective by the SEC within 90 days of the License Agreement execution.
- Final Agreement: The financial terms are based on a binding Term Sheet; the final License Agreement must be executed within 45 business days.
- Redacted Information: Certain provisions of the Term Sheet have been redacted in the public filing.
Investor Verification Checklist
- Verify the execution of the final Intellectual Property License Agreement within the 45-business-day window.
- Confirm the receipt of the $5,000,000 cash up-front payment and the issuance of Sorrento stock.
- Monitor the status of the Form S-3 registration statement for the Sorrento stock component.
- Review the full text of the Term Sheet (Exhibit 10.1) for specific definitions of "milestone events" and royalty rates.
- Assess the impact of the $4,000,000 reimbursement cap on Dyadic's historical development costs.